Novation and CTx in oncology collaboration
This article was originally published in Scrip
Executive Summary
Novation Pharmaceuticals and Cancer Therapeutics CRC (CTx) are to collaborate to identify small-molecule compounds for two intractable oncology targets, c-myc and hSSB1.